Premium
A single‐center COVID ‐19 vaccine experience with CoronaVac and BNT162b2 in familial Mediterranean fever patients
Author(s) -
Güven Serdar Can,
Karakaş Özlem,
Atalar Ebru,
Konak Hatice Ecem,
Akyüz Dağlı Pınar,
Kayacan Erdoğan Esra,
Armağan Berkan,
Gök Kevser,
Doğan İsmail,
Maraş Yüksel,
Erden Abdulsamet,
Erten Şükran,
Küçükşahin Orhan,
Omma Ahmet
Publication year - 2022
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.14349
Subject(s) - medicine , adverse effect , vaccination , covid-19 , booster dose , adverse event reporting system , demographics , pediatrics , immunology , infectious disease (medical specialty) , disease , immunization , antibody , demography , sociology
Aim To determine frequency of adverse events and attacks related to vaccination in recipients of CoronaVac and BNT162b2 in familial Mediterranean fever (FMF) patients, and to search whether history of prior COVID‐19 or a booster dose increases occurrence of adverse events/attacks. Methods FMF patients were surveyed for administration of any COVID‐19 vaccine and vaccine‐related adverse events or FMF attacks. Demographic, clinical, vaccine‐related data, history of COVID‐19 infection before or after vaccination, adherence to FMF treatment during vaccination were collected. Results A total of 161 vaccinated FMF patients were included. Ninety‐three patients out of 161 had reported suffering from an adverse event/attack after a vaccine dose. There were 54.7% of BNT162b2 recipients who reported any adverse event after any vaccine dose in comparison to 29.9% of CoronaVac recipients ( P < .001). There were 22.2% of BNT162b2 recipients who reported suffering from a FMF attack within 1 month after vaccination in comparison to 19.4% of CoronaVac recipients ( P = .653). When patients with or without adverse event/attack were compared, no significant differences were observed in means of demographics, comorbid diseases, disease duration, total vaccine doses, or treatments adhered to for FMF. Rates of adverse events/attacks were similar between patients with and without prior COVID‐19. In booster recipients, adverse events/attacks were most frequent after the booster dose. Conclusions A considerable number of FMF patients suffered from vaccine‐related adverse events/attacks, particularly with BNT162b2. No serious events or mortalities due to vaccination were detected. Demographics, clinical characteristics and prior history of vaccination did not significantly affect these results. We observed an increased rate of adverse events/attacks with booster dose administration.